Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of hAMSCs (Human Amniotic Mesenchymal Stem Cells) in preparing drug for treating acute graft-versus-host disease

A graft-versus-host, purpose-based technology, applied in the field of biomedicine, can solve problems such as allogeneic hematopoietic stem cell transplantation vs. host disease constraints

Inactive Publication Date: 2019-04-26
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the above-mentioned shortcomings of the prior art, the purpose of the present invention is to provide the use of human amniotic mesenchymal stem cells in the preparation of drugs for the treatment of acute graft-versus-host disease, which is used to solve the acute Graft-versus-host disease constraints and other issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of hAMSCs (Human Amniotic Mesenchymal Stem Cells) in preparing drug for treating acute graft-versus-host disease
  • Use of hAMSCs (Human Amniotic Mesenchymal Stem Cells) in preparing drug for treating acute graft-versus-host disease
  • Use of hAMSCs (Human Amniotic Mesenchymal Stem Cells) in preparing drug for treating acute graft-versus-host disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] 1. Isolation, culture, identification and labeling of hAMSCs

[0029] Fresh amniotic membranes voluntarily donated by healthy cesarean delivery women were selected (with the informed consent of the puerpera and approved by the hospital ethics committee); the fresh placenta discarded after delivery was taken under sterile conditions, and the amniotic membrane was bluntly separated from the chorionic villi; the rinsed placenta was bluntly separated. The amnion layer was cut into pieces with scissors, and the amniotic mesenchymal stem cells were gradually isolated and purified by the tissue block cell climbing out culture method; the third-generation amniotic mesenchymal stem cells were selected for surface marker identification and differentiation into osteoblasts, adipocytes, nerve cells, etc. Identification of differentiation ability;

[0030] 2. The immunoregulatory effect of hAMSCs on T lymphocyte subsets and related cytokines, compared with BMMSCs;

[0031] Establis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides use of hAMSCs (Human Amniotic Mesenchymal Stem Cells) in preparing a drug for treating the acute graft-versus-host disease. The hAMSCs can meet basic biological characteristicsof mesenchymal stem cells of adult tissues, also expresses an embryonic stem cell marker, and has multiplication capacity stronger than that of BMSCs (Bone Marrow Mesenchymal Stem Cells). When the hAMSCs and PHA (phytohemagglutinin) activated healthy human PBMCs (Peripheral Blood Mononuclear Cells) are co-cultured, the proportion of Th1 and Tc1 cell subsets is reduced, the proportion of Th2, Tc2 and Treg cell subsets is increased, the secretion level of IL-2 and IFN-gamma is reduced, the IL-10 level is increased, and therefore, the hAMSCs can be used for preparing the drug for treating the acute graft-versus-host disease.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the use of human amniotic mesenchymal stem cells in the preparation of medicines for treating acute graft-versus-host disease. Background technique [0002] Allogeneic hematopoietic stem cell transplantation (allogeneic Hematopoietic Stem Cell Transplantation, allo-HSCT) has been widely used in the treatment of blood system and non-blood system diseases, and even is the only way to cure some diseases. Acute graft-versus-host disease (aGVHD) is one of the main reasons restricting the curative effect of allo-HSCT. The pathogenesis of aGVHD is mainly due to the HLA incompatibility of the donor and the recipient to activate the donor's T lymphocytes and an abnormal immune response against the recipient's tissues and organs. The whole process involves various immune cell subsets, inflammatory mediators, intracellular transduction signals and gene expression regulation. The activation of T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28A61P37/06
CPCA61P37/06A61K35/28
Inventor 平宝红许影高雅孙海涛
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com